View in EDS

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.

Saved in:
Bibliographic Details
Title: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Authors: Gilbert, Lucy1 (AUTHOR) lucy.gilbert@mcgill.ca, Oaknin, Ana2 (AUTHOR) aoaknin@vhio.net, Matulonis, Ursula A.3 (AUTHOR) Ursula_Matulonis@dfci.harvard.edu, Mantia-Smaldone, Gina M.4 (AUTHOR) gina.mantia-smaldone@fccc.edu, Lim, Peter C.5 (AUTHOR) pclim@cohreno.com, Castro, Cesar M.6 (AUTHOR) cmcastro@mgh.harvard.edu, Provencher, Diane7 (AUTHOR) diane.provencher.chum@ssss.gouv.qc.ca, Memarzadeh, Sanaz8 (AUTHOR) smemarzadeh@mednet.ucla.edu, Method, Michael9 (AUTHOR) michael.method@immunogen.com, Wang, Jiuzhou9 (AUTHOR) joe.wang@immunogen.com, Moore, Kathleen N.10,11 (AUTHOR) kathleen-moore@ouhsc.edu, O'Malley, David M.1,12 (AUTHOR) David.O'Malley@osumc.edu
Source: Gynecologic Oncology. Mar2023, Vol. 170, p241-247. 7p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/j.ygyno.2023.01.020